TrialLeukemia2020

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Francesc Bosch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.